Literature DB >> 12106550

[The effects of implementing a smoking cessation intervention in Spain on morbidity, mortality and health care costs].

J González-Enríquez1, T Salvador-Llivina, A López-Nicolás, E Antón De Las Heras, A Musin, E Fernández, M García, A Schiaffino, I Pérez-Escolano.   

Abstract

OBJECTIVE: We estimated the effect that a smoking cessation intervention in the Spanish population of smokers would have on smoking-related morbidity, mortality and health care costs.
METHODS: We adopted the model Health and Economic Consequences of Smoking sponsored by the WHO Health Organization and developed by the The Lewin Group. The smoking cessation intervention proposed includes pharmacological treatment to 35% of smokers who are trying to quit smoking and obtains a quit rate of 7.2%. The diseases studied are: lung cancer, heart disease, stroke, chronic obstructive pulmonary disease, asthma exacerbation, and low birth weight. The smoking-related cases of disease and of averted death and the reduction in health care expenditure due to the intervention were estimated.
RESULTS: Without intervention, at year 1 of the model, 2,136,094 smokers would be affected by some smoking-related disease; health care expenditure would be 4,286 million e and deaths attributable to smoking would total 26,537. The proposed intervention would prevent 2,613, 9,192, 17,415 and 23,837 cases of smoking-related disease at years 2, 5, 10 and 20 of the model, respectively. The saving in accumulated health care costs would amount to 3.5 million e at year 2 and 386 million e over 20 years. The accumulated prevented deaths are 284 at year 2 and 9,205 over 20 years. The intervention would save a total of 78,173 life-years by the end of the period considered.
CONCLUSIONS: The availability of new effective smoking cessation interventions and the increase in accessibility to such interventions may contribute significantly to reducing morbidity, mortality and health care costs associated with smoking in Spain.

Entities:  

Mesh:

Year:  2002        PMID: 12106550     DOI: 10.1016/s0213-9111(02)71929-8

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  6 in total

1.  [Working with our smoker patients in primary care. Analysis of cost-effectiveness].

Authors:  Xulio Castañal-Canto; María Victoria Martín-Miguel; Cristina Hervés-Beloso; Santiago Pérez-Cachafeiro; María Mercedes Espinosa-Arévalo; José Luis Delgado-Martín
Journal:  Aten Primaria       Date:  2012-06-15       Impact factor: 1.137

2.  Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.

Authors:  Marta Trapero-Bertran; Celia Muñoz; Kathryn Coyle; Doug Coyle; Adam Lester-George; Reiner Leidl; Bertalan Németh; Kei-Long Cheung; Subhash Pokhrel; Ángel Lopez-Nicolás
Journal:  Addiction       Date:  2018-03-13       Impact factor: 6.526

3.  Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation.

Authors:  Kathryn Coyle; Doug Coyle; Adam Lester-George; Robert West; Bertalan Nemeth; Mickael Hiligsmann; Marta Trapero-Bertran; Reiner Leidl; Subhash Pokhrel
Journal:  Addiction       Date:  2017-09-14       Impact factor: 6.526

4.  [Cost-benefit of medical advice for quitting smoking in the Region of Murcia].

Authors:  Angel López-Nicolás; Marta Trapero-Bertran; Celia Muñoz
Journal:  Aten Primaria       Date:  2017-02-04       Impact factor: 1.137

5.  Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.

Authors:  Carlos A Jiménez-Ruiz; Segismundo Solano-Reina; Jaime Signes-Costa; Eva de Higes-Martinez; José I Granda-Orive; José J Lorza-Blasco; Juan A Riesco-Miranda; Neus Altet-Gomez; Miguel Barrueco; Itziar Oyagüez; Javier Rejas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-24

6.  Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study.

Authors:  Antoni Sicras-Mainar; Silvia Díaz-Cerezo; Verónica Sanz de Burgoa; Ruth Navarro-Artieda
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.